CLINICAL TRIALS PROFILE FOR ACALABRUTINIB

All Clinical Trials for acalabrutinib

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02029443 ↗	ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia	Active, not recruiting	Acerta Pharma BV	Phase 1/Phase 2	2014-01-30	This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
NCT02112526 ↗	Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma	Active, not recruiting	Acerta Pharma BV	Phase 1	2014-08-07	To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).
NCT02157324 ↗	Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia	Active, not recruiting	Acerta Pharma BV	Phase 1	2014-08-18	This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
NCT02180711 ↗	Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma	Recruiting	Acerta Pharma, LLC	Phase 1/Phase 2	2015-02-01	Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
NCT02180711 ↗	Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma	Recruiting	Acerta Pharma BV	Phase 1/Phase 2	2015-02-01	Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
NCT02180724 ↗	An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia	Active, not recruiting	Acerta Pharma BV	Phase 2	2014-09-08	The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.

Clinical Trial Conditions for acalabrutinib

Condition Name

Condition Name for acalabrutinib
Intervention	Trials
Chronic Lymphocytic Leukemia	33
Mantle Cell Lymphoma	23
Small Lymphocytic Lymphoma	14
Diffuse Large B Cell Lymphoma	6

Condition MeSH

Condition MeSH for acalabrutinib
Intervention	Trials
Lymphoma	65
Leukemia, Lymphocytic, Chronic, B-Cell	47
Leukemia, Lymphoid	45
Leukemia	40

Clinical Trial Locations for acalabrutinib

Trials by Country

Trials by Country for acalabrutinib
Location	Trials
United States	484
Canada	50
United Kingdom	40
Poland	25
France	19

Trials by US State

Trials by US State for acalabrutinib
Location	Trials
Texas	38
California	34
New York	31
Ohio	25
Florida	25

Clinical Trial Progress for acalabrutinib

Clinical Trial Phase

Clinical Trial Phase for acalabrutinib
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	17
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for acalabrutinib
Clinical Trial Phase	Trials
Recruiting	65
Not yet recruiting	23
Completed	22

Clinical Trial Sponsors for acalabrutinib

Sponsor Name

Sponsor Name for acalabrutinib
Sponsor	Trials
AstraZeneca	48
Acerta Pharma BV	44
National Cancer Institute (NCI)	18

Sponsor Type

Sponsor Type for acalabrutinib
Sponsor	Trials
Industry	120
Other	102
NIH	19